Image via Simply Wall St
Last updated
Twist Bioscience: Capital Raising
Twist Bioscience completed a US$300 million follow-on equity offering at US$96/share, upsized from an initially filed US$250 million raise. Concurrent with Q3 2026 results showing US$118.38M revenue and US$35.05M loss, company raised FY2026 guidance to US$456-457M.
Source: Simply Wall St
The leadership read
Twist Bioscience's raise resets the leadership agenda more than the balance sheet. Capital into Biotech & Pharma buys room to build senior operating and commercial bench strength ahead of scale. The near-term tilt favours operators who have scaled before; the appointments that follow say more than the announcement did across Americas.
Market context: Backdrop: a 100.3 (Neutral) Talent Market Index (down 1 on the month) with Americas activity easing (-1.8pts).
Twist Bioscience: 3 signals in the last 90 days — above the Biotech & Pharma median of 1 across 25 tracked companies; 0.1% of MitchelLake's Americas signal flow; 3 tracked across 56 days.
MitchelLake in this thematic
Also at Twist Bioscience →
More signals across Biotech & Pharma
Capital Raising · Americas
Ratio Therapeutics →Ratio Therapeutics closed a Series C funding round of $70M for radiopharmaceutical trials, led by existing investors Duquesne Family Office and Bristol Myers Squibb, with new investor participation.
Capital Raising · Americas
BridgeBio →BridgeBio secured funding to support drug launch; United Airlines made an investment into the cell therapy space
Capital Raising · Americas
Sana Biotechnology, Inc. →Schedule 13G filing indicates potential significant ownership change or investment activity
Geographic Expansion · Americas
UCB →UCB announces $2 billion investment in a new biomanufacturing campus in Georgia, expected to create 330+ jobs
Product Launch · Americas
Bristol Myers Squibb →FDA granted accelerated approval for iberdomide (marketed as Zenbexus), a multiple myeloma treatment for relapsed or refractory patients.
Ma Activity · Americas
Biogen →Biogen completed acquisition of RayThera Inc., with the acquired company's lead program now in Phase 1 development.
Where this lands in our work
- Executive Search →
Capital raised becomes leadership hired — the executive build follows the announcement.
- Executive Search — Americas →
Our Americas practice runs the searches behind signals like this one.
Intelligence powered by Autonodal ↗